Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases. Horizon's U.S. marketed products are ACTIMMUNE® (interferon gamma-1b), DUEXIS® (ibuprofen/famotidine), RAYOS® (prednisone) delayed-release tablets and VIMOVO® (naproxen/esomeprazole). The Company expects to begin marketing PENNSAID® (diclofenac sodium topical solution) 2% w/w in the U.S. in January 2015.
Horizon’s global headquarters are in Dublin, Ireland. The Company also has offices in Deerfield, Illinois; Roswell, Georgia; Reinach, Switzerland and Mannheim, Germany.
Elizabeth M. Higashi, CFA
Vice President, Investor Relations
Horizon Pharma plc
E. Blair Clark-Schoeb